Novartis gains momentum with strong performance in first half of 2008
- Details
- Category: Novartis

- First-half results for continuing operations led by improving Pharmaceuticals performance ahead of expectations and expansion in Vaccines and Diagnostics
- Net sales rise 11% (+2% in local currencies) to USD 20.6 billion
- Operating income advances 12% to USD 4.9 billion on business expansion, productivity gains and currency benefits
Abbott Reports Stronger-than-Expected Sales and Earnings Growth in Second Quarter
- Details
- Category: Abbott

- Diluted earnings per share, excluding specified items, were $0.84, above Abbott's previously announced guidance range of $0.78 to $0.80, reflecting 21.7 percent growth. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $0.85, up 34.9 percent.
Boehringer Ingelheim FENS Award for exceptional research in neuroscience
- Details
- Category: Boehringer Ingelheim

Novartis completes acquisition of 25% stake in Alcon from Nestlé
- Details
- Category: Novartis

Patients More Likely to Stay on Lipitor Than Simvastatin, a Large Observational Study Shows
- Details
- Category: Pfizer

Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case
- Details
- Category: Novartis

Shire proposes acquisition of Jerini AG for an equity purchase price of €328 million
- Details
- Category: Shire

More Pharma News ...
- Summary Judgment Granted for SEROQUEL Patent Litigation in the US
- GlaxoSmithKline responds to FDA on Cervarix® and plans to submit final study data for approval
- Novartis Institute for Tropical Diseases and Global Alliance for TB Drug Development
- Roche's tender offer to increase ownership stake in Chugai successful
- Abbott and Partnership for a Drug-Free America Launch 'Not In My House'
- Bayer concludes supply and licensing agreements for Yasmin® and YAZ® with Barr for the United Stat
- Cervarixâ¢, GSK's cervical cancer vaccine, wins tender for UK national immunisation programme